Navigation Links
Solos Endoscopy, Inc.'s Breast Endoscopy System Featured in February Issue of General Surgery News
Date:1/15/2010

BOSTON,  Jan. 15 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company's Breast Endoscopy System, the MammoView™, will be featured in a full-page advertisement in the February issue of General Surgery News. The publication, founded in 1972, is circulated to nearly 40,000 general and specialist surgeons each month throughout the United States.

General Surgery News is designed to keep general surgeons informed of the latest developments in the field. The publication features extensive meeting coverage, analysis of journal articles, educational reviews, and information on new drugs and products. General Surgery News' editorial focuses on such topics as prevention and management of health care, associated infections, breast cancer, surgical techniques, and endoluminal therapies.

"Solos Endoscopy is pleased to have its MammoView's™ instrument line displayed in one of the surgical industry's top magazines. The advertisement is the first in a year-long advertising campaign geared towards increasing the exposure of our entire Solos Endoscopy instrument line to potential customers and partners," stated Bob Segersten, President of Solos Endoscopy, Inc.

The advertisement will be available for preview on or before January 22, 2010 at www.solosendoscopy.com.

For more information on General Surgery News, please visit: www.generalsurgerynews.com

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.

RELATED LINKS
http://www.solosendoscopy.com

'/>"/>

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
2. Solos Endoscopy, Inc.s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress
3. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
4. Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line
5. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
6. Solos Endoscopy, Inc. Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Product Line
7. Solos Endoscopy, Inc. Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
8. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
9. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
10. Solos Endoscopy, Inc. Outlines Marketing Strategy for 2010 Campaign
11. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the ... in the Washington D.C. metropolitan area. ... delivery of medications through the convenience of its patient-friendly mobile ... within one hour to any location in D.C. ... invaluable service to Washington D.C. ," says ...
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 18, 2017 , ... ... a transparent, verifiable database to help the cannabis industry move towards greater legitimacy. ... to deliver a faster technology with lower fees. Paragon will build a fully ...
(Date:8/19/2017)... San Diego, CA (PRWEB) , ... August 19, 2017 , ... ... Neo-Nazis, and the KKK by saying there are two sides. There are not two ... merely a way to rationalize violence and prejudice, and the NPEIV stands against all ...
(Date:8/18/2017)... , ... August 18, 2017 , ... More than 20,000 ... Republic of Congo (DRC) thanks to an ambitious venture that conjoined the passions of ... the generous support of the Liberty community. These shoes will save lives from the ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... edition of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting ... resources available for individuals with hearing impairments and shares the latest innovations in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, ... communities in east Texas, is launching a regional charity effort to provide publicity ... 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in ...
Breaking Medicine News(10 mins):